Janssen reports positive trial data for new two-drug HIV regimen

Janssen Sciences Ireland has announced data from new phase III clinical trials showing the benefits of a new two-drug treatment regimen for HIV.

The two studies were designed to assess the safety and efficacy of switching virologically suppressed patients from a three or four-drug antiretroviral regimen to the two-drug regimen of rilpivirine and dolutegravir.

This new regimen, which combines therapies from Janssen and ViiV Healthcare, was able to meet its primary endpoint of noninferiority at week 48, helping to reduce levels of HIV in the bloodstream.

Additionally, it was shown that the safety profile for rilpivirine and dolutegravir in the two studies was consistent with the product labelling for each medicine.

Lawrence Blatt, global research and development head for infectious diseases and vaccines at Janssen, said: "We are committed to exploring new combination therapies to improve the lives of those facing lifelong HIV treatment and these important results for a two-drug regimen support those efforts."

Detailed results from these studies will be presented at an upcoming scientific meeting, with regulatory submissions for the single-tablet regimen to be made in 2017.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.